1.

PACKAGING
Q1) What is meaning of packaging and classification of
packaging, short note on primary packaging
Packaging is classified into three levels based on its relationship with the
product and its role in the distribution chain.

1. Primary Packaging

Primary packaging is the material that comes into direct contact with
the product itself. It is the first layer of protection and the last layer seen
by the consumer before using the product.

 Main Functions:

o Protection & Preservation: To prevent chemical, biological,

or physical degradation of the medicine.

o Containment: To hold the product (solids, liquids, or semi-

solids) securely without leakage.

o Compatibility: To ensure the material does not react with the

drug (non-reactive).

 Examples:

o Blister packs or Strip packs for tablets and capsules.

o Glass or Plastic bottles for syrups.

o Ampoules and Vials for injectables.

o Aluminium tubes for ointments and creams.

2. Secondary Packaging

Secondary packaging is the outer wrapping that holds one or more

primary packages together. It does not come into contact with the actual
medicine.

 Main Functions:

o Information & Branding: To display legal information,

dosage instructions, and brand identity.

o Physical Protection: To protect the primary container (like a

glass bottle) from breaking during storage.
 o Grouping: To organize individual units into a single retail sale
unit.

 Examples:

o Cardboard cartons (the box holding a blister pack or bottle).

o Labels attached to bottles.

o Leaflets/Inserts (Patient Information Leaflets).

o Trays used to hold ampoules inside a box.

3. Tertiary Packaging

Tertiary packaging (also known as bulk or transport packaging) is used to

group large quantities of secondary packages for high-volume shipping
and warehouse storage.

 Main Functions:

o Logistics & Transport: To facilitate the movement of goods

over long distances via road, air, or sea.

o Bulk Protection: To prevent crushing and damage during

heavy handling.

o Space Efficiency: To allow for stable stacking and easy

loading/unloading.

 Examples:

o Corrugated Shippers (brown fiberboard boxes).

o Pallets (wooden or plastic platforms used to stack shippers).

o Stretch wrap/Shrink wrap used to secure boxes on a pallet.

Q2) What are objectives of packaging

Packaging is defined as the technology used to protect, preserve, and
handle a product until it is consumed. Its primary objectives and functions
include:

 Protection and Preservation: The main objective is to protect

products from damage during transit and from environmental
factors such as contamination, moisture, humidity, gases,
microorganisms, insects, and light. It ensures the product retains its
stability and shelf-life.
  Containment and Waste Prevention: Packaging keeps products
together and prevents spillages or leakage, thereby reducing waste.

 Adulteration and Counterfeiting Control: It provides a

reasonable guarantee against product adulteration and serves as a
tool to control anti-counterfeiting.

 Information Display: Packaging acts as a medium to display vital

information, such as legal requirements, nutritional content,
manufacturing and expiry dates, and dosage instructions.

 Logistics and Transportation: It facilitates the transport of goods

over great distances and allows for efficient distribution. It also
saves space through stacking, which makes transport more efficient.

 Product Identification and Branding: Packaging helps in

identifying the product and protecting the brand image. It is often
referred to as a "silent salesman" because it aids in product
promotion and makes the product more convenient for the user.

 Safety and Security: Modern packaging objectives include

ensuring the product is tamper-evident, secure, and, in some cases,
child-proof.

Q.3) How to select packaging materials for

pharmaceutical products, Factors while choosing
packaging materials
Selecting the right packaging material is a critical process in
pharmaceutical development to ensure that the medication remains
stable, safe, and effective throughout its shelf life.

The selection process is generally guided by the following six key criteria:

1. Protection and Stability

The primary goal is to protect the drug from environmental degradation.

You must assess the product's sensitivity to:

 Moisture: For highly moisture-sensitive tablets, Alu-Alu (Cold-

form) blisters are preferred over standard PVC because they
provide a 100% barrier.

 Light: Light-sensitive formulations require Amber glass or opaque

foils to prevent photo-degradation.
  Gases/Oxygen: Some products require high-barrier plastics or
glass to prevent oxidation.

 Microorganisms: The packaging must maintain sterility and

prevent bacterial ingress.

2. Compatibility

The material must be "inert," meaning it does not react with the drug.

 Leachable/Extractable Testing: Ensure that no chemicals from

the plastic or rubber stopper migrate into the medicine.

 Hydrolytic Resistance: For liquid injectables, Type I Borosilicate

glass is selected for its high chemical resistance, preventing the
glass from reacting with the liquid.

3. Dosage Form and Route of Administration

The physical form of the medicine dictates the package type:

 Solid Orals (Tablets/Capsules): Usually packed in Blisters (for

unit-dose hygiene) or Strip packs.

 Semi-solids (Creams/Ointments): Packed in Aluminium

collapsible tubes because they don't suck air back in, maintaining
a sterile environment.

 Liquids/Injectables: Stored in Vials or Ampoules for easy

measurement and administration.

4. Safety and Security

 Tamper-Evidence: The packaging should clearly show if it has

been opened (e.g., breakable seals or blister pockets).

 Child-Resistance: For certain high-potency drugs, "Child-Resistant"

(CR) closures or specialized blister foils are used.

 Anti-Counterfeiting: Features like holograms, specialized printing,

or unique QR codes help protect the brand and patient safety.

5. Cost-Effectiveness and Logistics

 Durability: Materials must withstand the rigors of transportation.

For example, while glass is a great barrier, Plastic (HDPE) bottles
are often chosen for bulk tablets because they are lightweight and
non-fragile, reducing shipping costs and breakage.

 Manufacturing Efficiency: The material must be compatible with

high-speed packaging machinery without causing frequent jams or
defects.
6. Regulatory Compliance and Quality

 Pharmacopoeial Standards: Materials must comply with

standards like USP <660> (Glass) or USP <661> (Plastics).

 Vendor Selection: It is vital to choose vendors who provide a

Certificate of Analysis (COA) and maintain consistent quality
standards to ensure every batch of packaging meets the established
specifications.

Name the type of tube and advantage of aluminium

tube
A tube is a primary packaging format consisting of a cylindrical, hollow
body with a round or oval profile, made from metal or plastic. Invented by
John Goffe Rand in 1841, a tube is characterized by having one end closed
with a cap or closure and the other end sealed by either welding or
folding

The primary types of tubes used in pharmaceutical packaging include

Aluminium Collapsible Tubes, Laminated Tubes (Lami Tubes), and
Co-extrusion Tubes.

Aluminium tubes are particularly valued in the industry for their protective
and functional properties.

Types of Tubes

 Aluminium Collapsible Tubes: Made from 99.7% pure aluminum

slugs, these are the traditional choice for ointments and creams.

 Laminated Tubes (Lami Tubes): These consist of multiple layers

(typically three to five) of different materials, such as plastic and
aluminum, welded together.

o ABL (Aluminum Barrier Laminate): Includes an enclosed

aluminum barrier for high protection.

o PBL (Plastic Barrier Laminate): Uses a plastic barrier like

EVOH (ethylene vinyl alcohol copolymer).

 Co-extruded Tubes: These are formed by melting multiple

thermoplastic materials together into a single, inseparable
structure.

Advantages of Aluminium Tubes

  Superior Protection: They are airtight, impermeable, and
corrosion-resistant, providing an excellent barrier against moisture,
light, oxygen, and microorganisms.

 Hygienic and Non-Toxic: They are non-absorbent and do not

impart any taste, odor, or color to the medicinal contents.

 Prevents Air Intake: Because the material is deformable and does

not "spring back" (low resilience), it remains collapsed after
squeezing, which prevents air and contaminants from being sucked
back into the tube.

 Full Product Usage: Unlike plastic tubes, aluminum tubes can be

rolled and squeezed to ensure the user can extract the product to
the last drop.

 Sustainability: Aluminium is infinitely recyclable. Approximately

75% of all aluminium ever produced is still in use today.

 Anti-Counterfeiting: Once used and collapsed, these tubes cannot

be easily refilled or reused.

 Sterile Options: They can be sterilized using gamma radiation,

making them suitable for sensitive products like ophthalmic (eye)
ointments.

What is advantage of blister packaging over glass

packaging for tablets, short note on blister foil
Blister packaging is a widely used form of unit-dose packaging in the
pharmaceutical industry for tablets, capsules, and lozenges. It is also
known in some regions as a Push-Through-Pack (PTP). This packaging
consists of two primary parts: a formed cavity or pocket that holds the
product and a lidding material that seals it.

Key Components and Materials

 Forming Film: This creates the pockets and is typically made of

thermoformed plastic (such as PVC or PET) or cold-formed
laminate (Alu-Alu).

 Lidding/Lid Film: Usually made of aluminum foil, paper, or

polymer, it is heat-sealed to the forming film to create a barrier.

 Heat Seal Coating: An adhesive layer, often utilizing resins like

VMCH (Vinyl Chloride Vinyl Acetate Copolymer), is applied to
the foil to ensure a strong bond under heat and pressure.
Primary Types of Blister Packs

1. Thermoformed Blisters (PVC/PET): These are produced by

heating a plastic sheet and molding it into a "bubble" or pocket.
While cost-effective and transparent for easy product visibility, they
provide a poor barrier against moisture and oxygen.

2. Cold-Formed (Alu-Alu) Blisters: These are manufactured by

using mechanical pressure to press a laminate (sandwiched
aluminum foil) into a mold without heat. They offer superior
100% barrier protection against light, gases, and water vapor,
making them ideal for highly sensitive drugs

Blister packaging offers several advantages over glass packaging for

pharmaceutical tablets and capsules:

 Safety and Fragility: Blister packs are light and non-fragile,

meaning there is no chance of breakage as there is with glass
bottles.

 Hygienic Unit Dosing: Blister packaging is considered a very safe

and absolutely hygienic method for unit-dose packaging. It allows a
patient to consume a single tablet or capsule without touching or
exposing the other products in the pack.

 Protection: It provides a good degree of protection from both the

atmosphere and microorganisms. Specifically, cold-formed (Alu-Alu)
blisters offer 100% superior barrier protection against moisture and
light, which is ideal for sensitive drugs.

 User Convenience: Blister packs are convenient for administration

and do not require a "re-closer" as bottles do.

 Tamper and Mix-up Resistance: These packs provide a degree of

tamper resistance. Once a pocket has been broken, it cannot be
used again, and repacking is difficult. This helps secure the
pharmaceuticals against potential mix-ups.

 Product Integrity: Blister packaging helps maintain product

freshness for items designed for individual dispensing.

 Visibility: Because many blister packs use a transparent plastic

sheet, they provide a see-through package that allows for easy
visibility of the product.

 Strip packaging is a primary unit-dose packaging method for solid medicinal forms
such as tablets and capsules. Unlike blister packs that have a pre-formed cavity on
 one side, a strip pack is formed by sealing the medication between two layers of
flexible film.
 Manufacturing Principle
 The process involves two webs of heat-sealable flexible film—typically one printed
and one plain—that are passed through a pair of heated sealing rollers. These rollers
use a knurling pattern to create a strong seal around the product as it is fed from a
bowl through a chute

Why specification is required and write 5 prop

specification of glass bottle, carton short note on carton
Specifications are essential in pharmaceutical packaging because they
serve as a documented set of requirements that materials must satisfy to
ensure quality and safety. They act as a critical tool for checking material
quality and function as a "calculator" for evaluation.

Why Specifications are Required

 Agreement Document: They serve as a formal agreement

between the purchaser and the supplier.

 Decision Making: Materials are accepted or rejected based on

whether they meet the defined specifications.

 Variation Control: They help in controlling product variation to

ensure consistency across batches.

 Regulatory Compliance: Specifications ensure that packaging

meets technical and legal standards required for pharmaceutical
use.

Five Properties for Glass Bottle Specifications

When documenting a specification for a glass bottle, the following physical

and chemical properties are typically included:

1. Chemical/Hydrolytic Resistance: This classifies the glass (Type I,

II, III, or IV) based on its ability to resist water attack and alkaline
release, which is vital for product stability.

2. Dimensions and Tolerances: This includes precise measurements

of the bottle's height, body diameter, and neck dimensions (inner
and outer diameter).

3. Material Composition: The specific grade of glass and its

chemical makeup (e.g., percentage of silica, boric oxide, or sodium
oxide) must be defined.
 4. Light Transmission/Color: Specifications define the color (such as
Amber or Flint) and its ability to protect light-sensitive contents from
UV rays.

5. Capacity and Weight: The fill volume (e.g., 100 ml) and the
weight of the empty bottle are standardized to ensure uniformity.

What is pouch sachet and name type of material for

pouch
A pouch or sachet is a form of flexible packaging that uses non-rigid
materials. These containers are made from elastic-flexible materials that
are easily formed after being filled with a product, and they are capable of
bending or moving easily without breaking.

While pouches and sachets are both flexible bags, sachets are often
specifically used for unit doses of powders and granules.

Types of Materials for Pouches and Sachets

Pouches are typically made by joining two or more flexible webs through a
process called lamination, using materials like films, papers, or
aluminum foils.

Commonly used materials include:

 Polymer/Plastic Films: * Linear Low-Density Polyethylene

(LLDPE): Known for being very durable with superior impact
resistance.

o Low-Density Polyethylene (LDPE): Important for its

flexibility, tensile strength, and durability; often used for
products like milk pouches.

o High-Density Polyethylene (HDPE): An additive-free

material with high strength and clarity, frequently used for
vacuum packaging.

o Polypropylene (PP): Includes Cast PP (CPP) and Biaxially

Oriented Polypropylene (BOPP), which is stretched in two
directions for extra strength.

o Polyester (PET): Highly stiff and glossy films.

 Paper: Including Kraft, Glassine, Chromo, and Poster paper.

 Aluminum Foil: Used to provide a high-quality barrier against light,

moisture, and gases.
  Metallized Substrates: Such as metallized polyester film.

 Cellulosic Film: Another flexible substrate option.

Common Laminated Structures

To create secure barriers, manufacturers often combine these materials

into multi-layer structures, such as:

 Glassine Paper / PE / Aluminum Foil / PE

 PET / PE / Aluminum Foil / PE

 Polyester Film / Aluminum Foil / LDPE Film

Short note on import aspect of packaging

Name three instrument to test pacakaging material
What is advantage of plastic containers for pharma and
food

2. Labelling
Q.1 Objectives , definition of labelling
Labelling is an informative component of a product's package that
defines the product, its contents, and provides essential details regarding
its usage and safety. In the pharmaceutical industry, labelling must
include specific technical and regulatory information such as the official
product name, active and inactive ingredients, and directions for use.

The primary objectives of labelling are to provide essential information,

ensure safety, and aid in the marketing and legal compliance of a product.
According to the sources, the key objectives include:

 Product Identification and Recognition: Labelling serves to

assist in the identification and recognition of a product, helping
consumers distinguish a specific brand from competing items.

 Defining Product Contents and Usage: A core objective is to

inform the consumer about what the product contains and how it
should be used. This includes providing directions for use,
preparation instructions, and explaining the product's purpose.
  Ensuring Safety and Providing Warnings: Labels are designed
to communicate necessary cautions, potential allergic reactions, and
safety warnings to the user.

 Legal and Statutory Compliance: Labelling must ensure the

product adheres to legal requirements by including mandatory
information and statutory warnings, such as health warnings on
tobacco products.

 Product Promotion: An objective of labelling is to assist in the

promotion of products by giving customers a reason to purchase,
often through messages about savings or extra value.

 Classification and Assorting: Labelling allows for the "assorting"

of products, which involves grading or classifying items into different
categories, such as hair types for shampoos, to help consumers find
the correct version for their needs.

 Brand Protection and Anti-Counterfeiting: In the context of

packaging and labelling, an important objective is to protect the
brand image and control anti-counterfeiting measures.

 Providing Detailed Technical and Regulatory Data: Especially

in pharmaceuticals, labels objective is to display critical data such
as the manufacturer’s address, net weight, expiry dates, batch
numbers, and specific regulatory symbols like "Rx".

Q.2 Functions of labelling

Required Information on a Label

The sources specify that a label should typically show the following
information:

 Manufacturer Details: Name and address of the manufacturer or

importer.

 Product Composition: A clear description of what the product

contains.

 Measurements: Net weight or volumetric measurement.

 Product Life and Batch Info: Expiry date (EXP), Batch/LOT

number, and the duration of the product's life.

 Instructions and Storage: Directions for use, required storage

conditions (especially after opening), and manufacturer’s
instructions.
  Mandatory Pharmaceutical Data: Generic and brand names,
strength, pack size, "Rx" symbol, NDC code (for the US), bar codes,
and license numbers.

 Safety Information: Warnings, potential allergic reactions, and

cautions.

Q.2 Basic requirement in pharma labelling

The basic requirements for pharmaceutical labeling include a
comprehensive set of technical, legal, and safety-related information to
ensure proper use and regulatory compliance. According to the sources,
these requirements are categorized as follows:

1. Product Identification and Formulation

 Names: Both the Generic Name and the Brand Name (or Official
product name) must be clearly displayed.

 Strength and Composition: The label must state the strength of

the drug and provide a clear description of its composition,
including both active and inactive ingredients.

 Measurements: It must include the pack size, net weight, or

volumetric measurement of the product.

2. Regulatory and Tracking Data

 Manufacturing Details: The Batch Number, LOT number, and

License Number (Lic No.) are mandatory for tracking and are
considered critical parameters.

 Product Life: The Expiry Date (EXP) and the total duration of the
product's life must be shown.

 Entity Information: The name and address of the manufacturer

or importer, often accompanied by the company logo, must be
present.

 Codes and Symbols: Labels must include the Rx symbol, NDC

Code (specifically for the US market), and relevant bar codes (such
as 1D, 2D, or 3D/QR codes).

3. Usage, Storage, and Safety

 Instructions: Mandatory information includes directions for use,

the purpose and use of the medication, and any specific
manufacturer’s instructions for preparation.
  Storage: The label must define storage conditions, specifically
noting requirements after the package has been opened.

 Safety Notices: It is essential to include warnings, cautions, and

information regarding potential allergic reactions.

 Legal Compliance: Labels must strictly govern and display any

statutory warnings required by law, such as those found on
tobacco or specialized drug products.

4. Technical and Quality Requirements

 Overprinting: Sufficient space (such as an overprinting zone)

must be allocated for dynamic data like batch info and dates.

 Legibility: All printed matter, including text and artwork, must be

sharp and legible to avoid being classified as a defect.

 Item Identification: Labels should feature a unique item code for

inventory and internal tracking.

3. QC and QA
Write improvement objectives of quality control and
disadvantage of quality control
The following are the improvement objectives and disadvantages of
quality control as detailed in the sources:

Improvement Objectives of Quality Control

The primary aim of quality control is to maintain standards by testing

samples against specifications and providing feedback. Its key objectives
include:

 Finding Variations: Identifying variations in raw materials to

ensure consistency.

 Production Stability: Ensuring smooth and uninterrupted

production.

 Process Evaluation: Evaluating current production methods and

processes to suggest further improvements in their functioning.
  Data-Driven Feedback: Collecting data from testing to provide
feedback to the producer, thereby improving the value of
inspection and checking activities.

Disadvantages of Quality Control

The sources highlight several disadvantages, particularly regarding the

inspection and testing processes central to quality control:

 High Costs: It is costly because the people checking the material

are not the ones producing it.

 Reactive Nature ("Too Late"): Inspection alone adds nothing to

the quality of a product; it is performed after production and
serves only to filter out poor quality that has already been created.

 Unreliability: Studies show that human visual deficiencies can

cause inspectors to miss significant defects. Additionally, there is
often variation between individual judgments.

 Limited Scope: Quality control cannot address issues with

design or specifications; it can only check the product against
existing specifications and will not highlight if those specifications
themselves are deficient.

 Misplaced Responsibility: It can create a culture where quality

is viewed as the sole responsibility of the inspector rather
than the production team.

 Product Focus: It concentrates heavily on the final product

rather than the process used to create it.

Short note on quality control and quality assurance

Difference between quality control and quality
assurance
The core differences between Quality Control (QC) and Quality Assurance
(QA) lie in their focus, methods, and timing within the production process.
While they are both essential elements of quality management, they serve
distinct roles in ensuring a product meets its requirements.

1. Prevention vs. Detection

 Quality Assurance (QA) is a proactive and prevention-based

concept. Its primary goal is to prevent mistakes and defects in
manufactured products and avoid problems during delivery to
 customers. It focuses on providing confidence that quality
requirements will be fulfilled.

 Quality Control (QC) is a reactive and detection-based

process. It focuses on identifying and filtering out
unacceptable products after they have been produced by testing
samples against established specifications.

2. Process vs. Product Focus

 Quality Assurance is process-oriented. It involves the entire

system of production, including technology transfer, validation,
and documentation. It utilizes the PDCA cycle (Plan, Do,
Check, Act) to manage quality throughout the product's lifecycle.

 Quality Control is product-oriented. It concentrates on the

physical product rather than the process used to create it. Its main
activities include inspection, checking, and testing of raw
materials and finished goods.

3. Key Activities

The sources highlight specific activities that define each field:

 QA Activities: Quality audits, defining processes, tool

identification and selection, training on quality standards, and
establishing validation master plans.

 QC Activities: Testing (chemical, physical, biological), inspection

of materials (e.g., glass bottles, cartons, foils), and checkpoint
reviews.

4. Scope and Limitations

 Quality Assurance has a broader scope, addressing areas that QC

cannot, such as design and specification. It is considered the
"sum total of activities" aimed at achieving required standards.

 Quality Control is limited because it is often "too late"—it only

filters out poor quality that has already been created and does not
add quality to the product itself. Additionally, inspection can be
unreliable due to human error or variation in judgment.

Summary Table of Differences

Feature Quality Assurance (QA) Quality Control (QC)

Focus Prevention of defects Detection of defects

Orientati Process-oriented Product-oriented

on

Provide confidence in Identify variations in

Goal
quality materials

Testing, inspection,
Methods PDCA cycle, audits, training
sampling

Performed during process Performed after

Timing
design production

Quality in the context of pharmaceutical packaging is defined as

achieving customer satisfaction. It ensures that packaging materials
protect the product's stability and shelf-life from the time of
manufacture until consumption, allowing materials to pass through
production lines without hazards. Quality is considered a strategic issue
essential for protecting brand image, maintaining global consistency, and
controlling anti-counterfeiting

2. Stability studies

1. why stability studies carried out

Stability studies are conducted to ensure the quality, safety, and efficacy
of pharmaceutical materials over time. According to the sources, these
studies are carried out for the following primary reasons:

 To Provide Evidence of Quality Variation: Stability testing

provides evidence on how the quality of a drug substance or drug
product varies over time under the influence of environmental
factors such as temperature, humidity, and light.

 To Establish Retest Periods and Shelf Life: A fundamental goal

is to determine the appropriate re-test period for drug substances
(the time after which the material must be examined for
compliance) and the shelf life for drug products (the period the
product is expected to remain within specifications).

 To Determine Storage Conditions: These studies allow

manufacturers to identify and recommend specific storage
conditions that must be included on the product label to maintain
its integrity.
  To Ensure Safety and Compliance: Stability studies are a
regulatory requirement for registration applications of new
molecular entities and associated products. They provide
assurance to patients that the drug will remain safe and effective
until its expiration date.

 To Validate Packaging: Testing confirms that the formulation

remains within its physical, chemical, and microbiological
specifications when stored in its specific container closure
system.

 To Understand Degradation Pathways: Stress testing and forced

degradation studies help identify likely degradation products,
establish degradation pathways, and validate the power of
analytical methods.

 To Support Economic and Legal Interests: Carrying out these

studies fulfills legal requirements and protects the manufacturer's
economic interests by ensuring only high-quality products reach the
market.

[Link] is bracketing with example

Bracketing is a reduced stability testing design where only samples
at the extremes of certain design factors (such as strength,
package size, or fill) are tested at all time points.

 Core Assumption: The design assumes that the stability of any

intermediate levels is accurately represented by the stability of
the extremes that are actually evaluated.

 Applicability: It is used for multiple strengths of identical or closely

related formulations (e.g., tablets made from the same granulation)
or different sizes/fills within the same container closure system.

 Example: If a drug is available in three strengths (50 mg, 75 mg,

and 100 mg) and three container sizes (15 ml, 100 ml, and 500
ml), a bracketing design would only test:

o The 50 mg and 100 mg strengths (the extremes).

o The 15 ml and 500 ml container sizes (the extremes).

o The intermediate 75 mg strength and 100 ml container are

not tested, as their stability is bracketed by the others.

 Key Risk: If the tested extremes show different stability profiles,

the intermediate levels are considered no more stable than the
 least stable extreme. For instance, if the 15 ml container is less
stable than the 500 ml one, the 100 ml size cannot be assigned a
shelf life longer than that of the 15 ml container.

[Link] is Matrixing with example

Matrixing is a reduced stability testing design in which a selected
subset of the total possible samples for all factor combinations is tested
at a specified time point. At a subsequent time point, a different subset of
samples for those same factor combinations is tested.

Key Principles of Matrixing

 Assumption: The design assumes that the stability of each subset

tested represents the stability of all samples at that specific time
point.

 Factors Involved: The samples being matrixed typically differ by

factors such as
different batches,
different strengths,
or different
sizes/fills of the same
container closure
system.

 Application: It is
most useful when
multiple design factors are involved and product stability is
predictable with low variability.

 Testing Requirements: Generally, all selected factor combinations

must still be tested at the initial and final time points, as well as at
the 12-month mark if long-term data for the full shelf life isn't yet
available.

Example of Matrixing

A common example is a "One-Half Reduction" strategy for a drug

product available in two strengths (S1 and S2) across three batches. In
this design, instead of testing every batch and strength at every month (0,
3, 6, 9, 12, 18, 24, 36), the schedule is reduced as follows:

 Batch 1 of Strength 1: Tested at 0, 3, 9, 12, 24, and 36 months

(skipping 6 and 18 months).
  Batch 2 of Strength 1: Tested at 0, 3, 6, 12, 18, and 36 months
(skipping 9 and 24 months).

 Batch 3 of Strength 1: Tested at 0, 6, 12, 18, and 36 months

(skipping 3, 9, and 24 months).

This same logic is applied to Strength 2, ensuring that at any given

intermediate time point (like 6 or 18 months), at least some batches of the
product are being evaluated to represent the whole.

Potential Risks

Because less data is collected, matrixing designs generally have less

precision in estimating shelf life compared to a full design. If the data
shows high variability, matrixing is considered inappropriate because it
may fail to detect differences in degradation rates among the different
factors.

[Link] are various pacakaging material

used during stabality data
Stability studies utilize several types of packaging materials, chosen
based on their compatibility with the drug and their ability to protect it
from environmental degradation. For a comprehensive 5-mark response,
the various materials are categorized as follows:

1. Glass

Glass is the most commonly used material because it is highly

resistant to chemical and physical changes.

 Borosilicate glass is used to overcome the natural alkalinity of

glass surfaces.

 Amber-colored glass is employed for light-sensitive drugs to

prevent photochemical decomposition.

 Buffers may be added to the formulation to prevent ions in the

glass from causing precipitation.

2. Plastics

Plastics are used for bottles and tubes, but they present specific stability
challenges that must be monitored:

 Migration: The drug may move through the plastic into the
environment.
  Permeation: Environmental moisture or oxygen may enter the
container.

 Leaching & Adsorption: Container ingredients may leach into the

drug, or the plastic may adsorb active drug components or
excipients.

3. Metals

Aluminum and various alloys are primarily used for semisolid dosage
forms like ointments, creams, and pastes.

 Internal Lacquering: To prevent the metal from causing corrosion

or drug precipitation, the tubes are often internally coated with
inert polymers.

4. Rubber

Rubber is mainly used for stoppers and closures in injection vials.

 Stability Issues: Like plastic, rubber can cause leaching or

ingredient extraction.

 Pretreatment: These components are typically pretreated with

water and steam to reduce the potential for leaching during the
stability period.

5. Standard Packaging by Dosage Form

During initial stress testing, standard inert materials are used to ensure
accurate kinetic data:

 Solid Dosage Forms: Typically packaged in 50-mL glass

containers with twist-off closures or polypropylene tubes.

 Semisolid Dosage Forms: Packaged in aluminum tubes

(internally lacquered) or standard plastic tubes.

 Liquid Dosage Forms: Utilizes ampoules, injection vials with

rubber stoppers, or glass/plastic bottles with screw closures. For
precise testing, 25-mL volumetric flasks with ground-glass stoppers
are also used.

5. how shelf life is estimated using stabality

study
To provide a comprehensive 5-mark response on how shelf life is
estimated using stability studies, the process can be divided into five key
technical stages based on ICH Q1A and Q1E guidelines:
1. Generation of Core Stability Data

Shelf life is estimated based on data from a minimum of three primary

batches of the drug substance or product. These batches are subjected
to three types of studies to determine their behavior over time:

 Long-term testing: Conducted at 25°C ± 2°C / 60% RH ± 5% RH

for at least 12 months to provide real-time data.

 Accelerated testing: Conducted at 40°C ± 2°C / 75% RH ± 5% RH

for 6 months to increase the rate of chemical degradation.

 Intermediate testing: Performed if "significant change" occurs

during accelerated testing (e.g., a 5% change in assay).

2. Sequential Attribute Assessment

Stability information should include results from physical, chemical,

biological, and microbiological tests.

 Individual Assessment: Each critical quality attribute (such as

assay, degradation products, pH, and dissolution) is assessed
separately.

 Shortest Period Rule: The proposed shelf life must not exceed
the time predicted for any single attribute to remain within its
acceptance criteria.

3. Statistical Analysis for Quantitative Data

For attributes that show change over time or variability, statistical

methods are used to pinpoint the exact end of the shelf life:

 Regression Analysis: The relationship between a quantitative

attribute and time is modeled (usually as a linear, quadratic, or
cubic function).

 Poolability Testing (ANCOVA): A statistical test with a

significance level of 0.25 is used to determine if data from different
batches can be combined. If batches are not poolable, the shelf life
is based on the shortest period supported by any individual batch.

 95% Confidence Limit: The shelf life is the time at which the 95%
one-sided confidence limit for the mean degradation curve
intersects the acceptance criterion.

4. Extrapolation Beyond Real-Time Data

Extrapolation is the practice of using known datasets to infer future

stability. The extent of extrapolation allowed beyond the period covered
by long-term data (X) depends on the study outcomes:
  Stable Data (No Change): Extrapolation can be up to 2X, but not
exceeding X + 12 months.

 Change with Statistical Support: If backed by analysis and

relevant supporting data, extrapolation up to 2X (max X + 12
months) may still be granted.

 Significant Change at Accelerated Condition: If no change is

seen at the intermediate condition, extrapolation is limited (e.g., up
to X + 6 months with statistical analysis).

 Significant Change at Both Conditions: No extrapolation is

permitted; the shelf life is based strictly on available long-term data.

5. Verification and Commitment

Any shelf life granted based on extrapolation must be verified by

additional long-term stability data as soon as they become available
from production batches. If the submitted data do not yet cover the full
proposed shelf life, the manufacturer must provide a stability
commitment to continue testing until the period is firmly established.

6. what do you mean by stabality

indicating method
A stability-indicating method (SIM) is a validated analytical procedure
that is capable of accurately and precisely measuring the active
pharmaceutical ingredient (API) without interference from degradation
products, process impurities, or excipients.

Key aspects of these methods include:

 Detection of Changes: Stability-indicating procedures are applied

to test attributes of a drug substance or product that are susceptible
to change during storage and are likely to influence quality, safety,
or efficacy.

 Resolution of Degradants: The method must be capable of

resolving and detecting degradation products (such as
photolytic degradants) that appear during stability studies.

 Validation via Stress Testing: The "stability-indicating power" of

an analytical procedure is validated through stress testing (or
forced degradation). This involves deliberately degrading the
sample under severe conditions—such as extreme heat, light,
oxidation, or a range of pH values—to ensure the test method can
distinguish the drug molecule from its likely degradation products.
  Support for Mass Balance: These methods are essential for
evaluating mass balance, which is the process of adding the assay
value and the levels of degradation products to see how closely they
total 100% of the initial value.

 Regulatory Requirement: According to ICH guidelines, fully

validated stability-indicating analytical procedures must be applied
in all formal stability studies used for registration applications.

[Link] details have to mentioned in

stabality report
To secure 3.5 marks, a stability report should cover these key areas
concisely:

 Test Results and Attributes: Comprehensive results from

physical, chemical, biological, and microbiological tests must be
included. This specifically covers assay levels, degradation
products, pH, and appearance.

 Data Presentation Formats: Data must be presented in tabular,

graphical, and narrative formats. Quantitative attributes (like
assay) should be reported exactly as measured, such as a
percentage of the label claim.

 Statistical Analysis Details: If a statistical analysis is performed,

the report must state the procedure used, the underlying
assumptions, and the results of "goodness of fit" tests for the
model. It should also include poolability test results if data from
different batches were combined.

 Mass Balance Evaluation: An assessment of the mass balance—

adding the assay value and degradation product levels to see if they
closely total 100% of the initial value—must be provided.

 Storage Conditions and Excursions: Detailed documentation of

the storage temperature and humidity is required. Any excursions
outside defined tolerances lasting more than 24 hours must be
described and evaluated for their impact.

 Conclusions and Labeling: A clear proposal for the re-test

period (drug substance) or shelf life (drug product). This must
include recommended labeling statements and specific storage
instructions, such as "Do not freeze" or "Protect from light".
  Photostability Findings: If applicable, the report must identify
necessary precautionary measures for manufacturing and whether
light-resistant packaging is required.

[Link] do you mean by significant change

during stabality testing
During stability testing, a significant change refers to a specific
degree of variation in the quality of a drug substance or drug
product that exceeds predefined limits. The definition differs
depending on whether a drug substance or a finished drug product
is being evaluated.

1. For Drug Substances

A significant change for a drug substance is simply defined as a

failure to meet its specification.

2. For Drug Products

For a drug product, a significant change is defined as the occurrence

of one or more of the following:

 Assay/Potency: A 5% change in assay from its initial value, or a

failure to meet the acceptance criteria for potency when using
biological or immunological procedures.

 Degradation Products: Any degradation product exceeding its

established acceptance criterion.

 Physical Attributes: Failure to meet acceptance criteria for

appearance, physical attributes, and functionality tests (e.g.,
color, phase separation, resuspendibility, caking, hardness, or dose
delivery).

o Note: Some physical changes, such as the softening of

suppositories or melting of creams, may be expected under
accelerated conditions and might not be considered a
"significant change" if they can be justified.

 pH Levels: Failure to meet the acceptance criterion for pH.

 Dissolution: Failure to meet acceptance criteria for dissolution for

12 dosage units.

o Note: For gelatin capsules or gel-coated tablets, failure to

meet dissolution criteria due to cross-linking can sometimes
be justified and not considered a significant change.
 3. Special Cases (Semi-Permeable Containers)

For aqueous-based products packaged in semi-permeable

containers (like plastic bags or LDPE bottles), a 5% loss in water
from the initial value is considered a significant change after three
months of storage at 40°C/NMT 25% RH. For very small containers
(1 mL or less), a loss of 5% or more may be acceptable if justified.

Testing Implications

If a "significant change" occurs during the 6 months of testing at the

accelerated storage condition (40°C ± 2°C / 75% RH ± 5% RH),
manufacturers are typically required to:

 Conduct additional testing at the intermediate storage condition

(30°C ± 2°C / 65% RH ± 5% RH).

 Include at least four time points (e.g., 0, 6, 9, and 12 months) in the

resulting 12-month intermediate study.

 Re-evaluate the proposed shelf life, as significant change at

accelerated or intermediate conditions severely limits the ability to
extrapolate data beyond the real-time long-term studies.

[Link] are difference between long term

and accelerated conditions 5 mark answer
In pharmaceutical stability testing, long-term and accelerated
conditions serve distinct purposes in determining a drug's quality
over time. A 5-mark answer detailing their differences is provided
below:

1. Core Objective and Definition

 Long-Term Testing: These studies are conducted under the

recommended storage conditions for the proposed or approved
shelf life. They provide real-time evidence of how quality varies over
the entire intended duration of use.

 Accelerated Testing: These studies use exaggerated storage

conditions to increase the rate of chemical degradation or physical
change. The goal is to predict longer-term chemical effects at non-
accelerated conditions and evaluate the impact of short-term
excursions (e.g., during shipping).

2. Storage Conditions (General Case - Climatic Zones I & II)

Feature Long-Term Accelerated

 Conditions Conditions

25°C ± 2°C or
Temperature 40°C ± 2°C
30°C ± 2°C

Relative 60% ± 5% or 65%

75% ± 5%
Humidity (RH) ± 5%

 Specific Storage: For products intended for a refrigerator, the

long-term condition is 5°C ± 3°C, while the accelerated condition is
25°C ± 2°C / 60% RH. For frozen products (-20°C), there is
generally no accelerated condition; testing is instead done at an
elevated temperature (e.g., 5°C) to address excursions.

3. Testing Frequency and Duration

 Long-Term Testing: For a proposed shelf life of at least 12 months,

testing is typically performed every 3 months in the first year,
every 6 months in the second year, and annually thereafter. A
minimum of 12 months of data is required at the time of
registration submission.

 Accelerated Testing: These studies usually last 6 months.

Sampling occurs at a minimum of three time points, typically 0, 3,
and 6 months.

4. Data Application and Shelf Life Estimation

 Long-Term Data: This is the primary basis for establishing the re-
test period for drug substances or the shelf life for drug products.

 Accelerated Data: This data is used to support extrapolation of

the shelf life beyond the period covered by long-term data. It also
helps identify likely degradation products and establish degradation
pathways during method development.

5. Regulatory Implications (Significant Change)

 If a "significant change" (such as a 5% potency loss) occurs under

accelerated conditions within 6 months, additional testing at
intermediate conditions (e.g., 30°C/65% RH) is mandated to
further evaluate stability. In contrast, a failure at the long-term
condition immediately defines the end of the product's valid shelf
life.
[Link] is photostability study? Draw the
decision flow chart for photostability testing
of drug substances.
What is a Photostability Study? A photostability study evaluates
the stability of a drug substance or drug product when exposed to
light to ensure that such exposure does not lead to unacceptable
changes in quality, safety, or efficacy. . These studies are an integral
part of stress testing and help determine the necessary handling,
packaging, and labeling requirements for the drug.

Photostability Testing of Drug Substances For drug substances,

photostability testing is divided into two distinct parts:
1. Forced Degradation Testing:
o Purpose: To evaluate overall photosensitivity for method
development and to elucidate degradation pathways.
o Conditions: Samples are placed in chemically
inert/transparent containers and exposed to various light
intensities.
o Outcome: Used to validate analytical procedures capable of
detecting photolytic degradants.
2. Confirmatory Testing:
o Purpose: To establish photostability characteristics under
standardized conditions and identify if light-resistant
packaging is required.
o Batch Selection: Normally conducted on a single batch; if
results are equivocal, up to two additional batches may be
tested.
o Judgment: Results are evaluated alongside other stability
data to ensure the drug remains within justified limits during
its shelf life.

[Link] are the light source used for

photostability testing? What is the
procedure for confirmatory studies
1. Photostability Study and Drug Substance Testing Process

2. Light Sources and Confirmatory Study Procedure

 Light Sources used for Testing
The sources define two options for light sources. The applicant can
rely on the spectral distribution specification provided by the
manufacturer.
 Option 1: Any light source designed to produce an output similar to
the D65/ID65 emission standard (the international standard for
outdoor and indoor indirect daylight). Examples include:
o Artificial daylight fluorescent lamps combining visible and UV
outputs.
o Xenon lamps.
o Metal halide lamps.
 Option 2: The same sample must be exposed to both of the
following:
1. Cool white fluorescent lamp (per ISO 10977 specifications).
2. Near UV fluorescent lamp with a spectral distribution of
320 nm to 400 nm and a maximum energy emission between
350 nm and 370 nm.
Procedure for Confirmatory Studies
To ensure direct comparisons can be made between drug
substances and products, the following standardized procedure is
followed:
 Exposure Requirements:
o Overall Illumination: Not less than 1.2 million lux hours.
o Integrated Near UV Energy: Not less than 200 watt
hours/square meter.
 Monitoring Exposure:
o Exposure is verified using a validated chemical
actinometric system (such as Quinine Chemical
Actinometry) or monitored with calibrated radiometers/lux
meters.
 Controls:
o Dark controls (samples wrapped in aluminum foil) should be
placed alongside the test samples to evaluate the contribution
of thermally induced changes to the total observed
change.
 Sample Presentation (Drug Substance):
o Solids: Should be spread in a suitable container (glass or
plastic) to a thickness of typically not more than 3
millimeters.
o Liquids: Should be exposed in chemically inert and
transparent containers.
  Analysis: At the end of the exposure, samples are examined for
changes in physical properties (appearance, color, clarity), assay,
and the presence of degradants using validated methods.

1. Explain extrapolation of data.

[Link] is full form of ICH? What are the

storage conditions of long term, accelerated
and intermediate
1. Full Form of ICH
The full form of ICH is the International Conference on
Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use. Some sources also refer to it as
the International Council for Harmonisation, reflecting its
ongoing mission to achieve greater global standardisation for safe
and effective medicines.

2. Storage Conditions for Stability Studies

The storage conditions used in stability testing depend on the
intended storage temperature of the drug and the climatic zone of
the intended market. The standard conditions for the General Case
(Climatic Zones I and II) are as follows:

Storage Condition Minimum

Type of
(Temperature & Duration at
Study
Humidity) Submission

25°C ± 2°C / 60% RH ±

Long-Term 5% RH or 30°C ± 2°C / 12 Months
65% RH ± 5% RH

Intermedi 30°C ± 2°C / 65% RH ±

6 Months
ate 5% RH

Accelerate 40°C ± 2°C / 75% RH ±

6 Months
d 5% RH

Special Storage Cases

 Refrigerator (5°C):
o Long-Term: 5°C ± 3°C.
o Accelerated: 25°C ± 2°C / 60% RH ± 5% RH.
 Freezer (-20°C):
o Long-Term: -20°C ± 5°C.
 o Note: There is no standard accelerated condition for frozen
products; instead, samples are tested at an elevated
temperature (e.g., 5°C ± 3°C or 25°C ± 2°C) to evaluate the
impact of short-term excursions, such as during shipping.
 Semi-permeable Containers (e.g., plastic bags for liquids):
o Long-Term: 25°C ± 2°C / 40% RH ± 5% RH or 30°C ± 2°C /
35% RH ± 5% RH.
o Accelerated: 40°C ± 2°C / Not More Than (NMT) 25% RH.
Key Rule: If 30°C ± 2°C / 65% RH ± 5% RH is chosen as the long-
term condition, an intermediate condition is not required.

2. Draw decision tree for data exclusion for retest or shelf-life

estimation for drug substance or product

Explain data evaluation for drug substance

or product intended for the storage below
room temperature
For drug substances or products intended for storage below room
temperature, data evaluation follows specific protocols based on the
intended storage condition (refrigerator, freezer, or below -20°C).
The primary goal is to determine a retest period or shelf life based
on the observed stability under long-term and accelerated
conditions.
1. Storage in a Refrigerator (5°C)
Evaluation for refrigerated products generally follows the same
principles as room temperature storage, but with more limited
allowances for extrapolation.
 No Significant Change at Accelerated Condition (25°C/60%
RH):
o If little or no change/variability is seen: The shelf life or
retest period can be proposed for up to 1.5 times the period
covered by long-term data (X), but not exceeding X + 6
months.
o If change or variability is seen (without statistical
analysis): Extrapolation is limited to 3 months beyond X,
provided it is backed by relevant supporting data.
o If change or variability is seen (with statistical
analysis): If backed by a validated statistical model and
supporting data, the period can be up to 1.5 times X, not
exceeding X + 6 months.
 Significant Change at Accelerated Condition:
 o If significant change occurs between 3 and 6 months of
accelerated testing, the shelf life must be based strictly on
available real-time long-term data; no extrapolation is
permitted.
o If significant change occurs within the first 3 months, the
shelf life is based on long-term data. Additionally, the
manufacturer must provide a discussion or further testing
results (e.g., on a single batch for less than 3 months) to
address the impact of short-term excursions outside the
label storage condition (like during shipping).
2. Storage in a Freezer (-20°C)
The requirements for frozen products are more stringent because
there is typically no standard accelerated storage condition for this
temperature.
 Basis for Shelf Life: The retest period or shelf life must be based
strictly on real-time data obtained at the long-term storage
condition (-20°C ± 5°C).
 No Extrapolation: Unlike refrigerated or room-temperature
products, no extrapolation of data is allowed beyond the period
covered by long-term studies.
 Addressing Excursions: To evaluate the effect of short-term
excursions (e.g., shipping/handling), testing should be conducted on
a single batch at an elevated temperature (such as 5°C ± 3°C
or 25°C ± 2°C) for an appropriate duration.
3. Storage Below -20°C
Drug substances or products intended for storage below -20°C are
handled on a case-by-case basis. The proposed retest period or
shelf life must be based on available long-term data.
Summary Table for Extrapolation (Below Room Temp)

Intended Accelerated Max Extrapolation

Storage Result Allowed

No Significant Up to 1.5X (Max X + 6

Refrigerator
Change months)

Significant
Refrigerator No Extrapolation
Change

Freezer N/A No Extrapolation

Note: "X" represents the period covered by available long-term data

at the time of submission.

3. Explain general statistical approaches